UCB buoyed by strong first half; lupus ambitions undented despite PhIII upset
This article was originally published in Scrip
The mid-sized European pharma company UCB is accelerating its investment in its early-stage portfolio following the continuing sales growth of its three core marketed products, and is also advancing a second potential lupus drug into Phase II trials following disappointing Phase III results reported earlier this week for its first lupus drug epratuzumab.
You may also be interested in...
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.